The FDA approved Merck's RotaTeq vaccine against rotavirus, a virus that affects most young children and often is fatal in developing countries. In response to problems with an earlier vaccine, Merck and competitor GlaxoSmithKline conducted trials to ensure their vaccines do not cause dangerous obstructions of the intestine.

Related Summaries